Citadel Advisors’s ENDRA Life Sciences NDRA Stock Holding History

Citadel Advisors’s Portfolio NDRA Stock Details NDRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-21	Closed	-$52.1K	–	14811
2023 Q2	$52.1K	Buy	+21	New	+$59.1K	﹤0.01%	11750
2022 Q4	–	Sell	-2	Closed	-$23K	–	15252
2022 Q3	$23K	Buy	+2	New	+$20.7K	﹤0.01%	12022
2022 Q1	–	Sell	-1	Closed	-$34K	–	14241
2021 Q4	$34K	Buy	+1	New	+$42.5K	﹤0.01%	13425
2021 Q3	–	Hold	0	–	–	–	13603
2021 Q2	–	Sell	-1	Closed	-$130K	–	14140
2021 Q1	$130K	Buy	+1	New	+$74.9K	﹤0.01%	12201
2020 Q4	–	Sell	-1	Closed	-$33K	–	11302
2020 Q3	$33K	Hold	1	–	–	﹤0.01%	9738
2020 Q2	$36K	Buy	+1	New	+$29K	﹤0.01%	9416
2019 Q2	–	Sell	-1	Closed	-$29K	–	9623
2019 Q1	$29K	Buy	+1	New	+$73K	﹤0.01%	9003
2018 Q4	–	Hold	0	–	–	–	8733

Other funds holding NDRA

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NewEdge Advisors New Orleans, Louisiana $27.7B AUM 22.98% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

VNA

Valley National Advisers Bethlehem, Pennsylvania $900M AUM 31.19% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Citadel Advisors's NDRA Position: Q3 2023 in Review

Citadel Advisors sold out of ENDRA Life Sciences (NDRA) in Q3 2023, closing a stake of 21 shares — an estimated $52.1K sold.

Citadel Advisors first reported a position in NDRA in Q1 2019 and held it in 7 quarters. The position peaked at $130K in Q1 2021. 5 funds tracked by Wall St. Rank hold NDRA as of Q3 2023.

Citadel Advisors reported no remaining ENDRA Life Sciences position as of Q3 2023 after selling out during the quarter.
Citadel Advisors sold 21 ENDRA Life Sciences shares in Q3 2023, an estimated $52.1K.
Citadel Advisors first reported a position in ENDRA Life Sciences in Q1 2019 and held it in 7 quarters.
Citadel Advisors's ENDRA Life Sciences position peaked at $130K in Q1 2021.
5 funds tracked by Wall St. Rank held ENDRA Life Sciences as of Q3 2023.

Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.